Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo, MC Salvetti… - Thrombosis research, 2020 - Elsevier
Abstract Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …
被引用次数：313 相关文章

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).

ACB Lemos, MC Salvetti, RN Gilio, LB Agra… - Thrombosis …, 2020 - europepmc.org
Methods In this randomized, open-label, phase II study, we randomized COVID-19 patients
requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard …
[PDF] ascardio.info

[PDF][PDF] Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo, MC Salvetti… - Thrombosis …, 2020 - ascardio.info
ABSTRACT Introduction: Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods …

[引用][C] Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo, MC Salvetti… - Thrombosis …, 2020 - cir.nii.ac.jp
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase
II clinical trial (HESACOVID) | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo… - Thrombosis …, 2020 - thrombosisresearch.com
Abstract Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods In …

[引用][C] Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA Espírito Santo, MC Salvetti… - Thrombosis …, 2020 - repositorio.usp.br
ReP USP - Detalhe do registro: Therapeutic versus prophylactic anticoagulation for severe
COVID-19: a randomized phase II clinical trial (HESACOVID) Home About USP Schools …

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo… - Thrombosis …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state.
Several autopsy studies have found microthrombi in pulmonary circulation. Methods In this …

Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID).

ACB Lemos, DAE Santo, MC Salvetti, RN Gilio… - 2020 - cabidigitallibrary.org
Abstract Introduction: Coronavirus disease 2019 (COVID-19) causes a hypercoagulable
state. Several autopsy studies have found microthrombi in pulmonary circulation. Methods …
[HTML] nih.gov

[HTML][HTML] Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

ACB Lemos, DA do Espírito Santo… - Thrombosis …, 2020 - ncbi.nlm.nih.gov
Methods In this randomized, open-label, phase II study, we randomized COVID-19 patients
requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard …

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID).

ACB Lemos, MC Salvetti, RN Gilio, LB Agra… - Thrombosis …, 2020 - europepmc.org
Methods In this randomized, open-label, phase II study, we randomized COVID-19 patients
requiring mechanical ventilation to receive either therapeutic enoxaparin or the standard …